Our discovery and development platforms for drug and cell-based therapies allow us to both create and retain significant value within our therapeutic franchise areas of cancer and inflammatory diseases. Scientists and physicians at Celgene are the driving force behind our success, enabling target-to-therapeutic platforms that integrate both small-molecule and cell-based therapies.
Leading-edge scientific research in oncology remains our passion. We are focused on developing disruptive approaches to high value disease pathways that translate into life-enhancing medicines with the ultimate goal to change the course of human health while promising to always put patients first.
The Connect® Registries are observational, hematologic patient registry studies in Multiple Myeloma (Connect®MM), Chronic Lymphocytic Leukemia (Connect®CLL) and Myelodysplastic Syndromes/Acute Myeloid Leukemia (Connect®MDS/AML) and are sponsored by Celgene Corporation. These studies are designed to observe the routine care of patients through the course of their disease. Unlike clinical trials, registries do not require or provide any specific medications or healthcare services, but leave those decisions to the treating doctors and their patients.